source
- Phase 3 STRIKE trial to assess disease-free survival of adjuvant tivozanib plus pembrolizumab in high-risk RCCDr. Bradley McGregor, director of clinical research at the Lank Center of Genitourinary Oncology, outlined the key objectives of the ongoing phase 3 STRIKE trial (NCT06661720). The study evaluates…
- Top Breast Cancer Experts Highlight Key Abstracts Ahead of 2026 ESMO Congress in BerlinLeading breast oncologists are sharing the abstracts they consider most important as the European Society for Medical Oncology (ESMO) Breast Cancer Congress approaches in Berlin from May 6 to 8, 20…